scholarly journals Safety and Immunogenicity of a Novel Recombinant Simian Adenovirus ChAdOx2 as a Vectored Vaccine

Vaccines ◽  
2019 ◽  
Vol 7 (2) ◽  
pp. 40 ◽  
Author(s):  
Pedro M. Folegatti ◽  
Duncan Bellamy ◽  
Rachel Roberts ◽  
Jonathan Powlson ◽  
Nick J. Edwards ◽  
...  
Keyword(s):  
Immune Responses ◽  
Mycobacterium Avium Subspecies Paratuberculosis ◽  
Intracellular Pathogens ◽  
Neutralising Antibodies ◽  
Dose Escalation Study ◽  
Cellular Immune Responses ◽  
Simian Adenovirus ◽  
Adenovirus Vectors ◽  
Vectored Vaccine ◽  
Cellular Immune

Adenovirus vectored vaccines are a highly effective strategy to induce cellular immune responses which are particularly effective against intracellular pathogens. Recombinant simian adenovirus vectors were developed to circumvent the limitations imposed by the use of human adenoviruses due to widespread seroprevalence of neutralising antibodies. We have constructed a replication deficient simian adenovirus-vectored vaccine (ChAdOx2) expressing 4 genes from the Mycobacterium avium subspecies paratuberculosis (AhpC, Gsd, p12 and mpa). Safety and T-cell immunogenicity results of the first clinical use of the ChAdOx2 vector are presented here. The trial was conducted using a ‘three-plus-three’ dose escalation study design. We demonstrate the vaccine is safe, well tolerated and immunogenic.

De novo syntheses of Marburg virus antigens from adenovirus vectors induce potent humoral and cellular immune responses

Vaccine ◽  
2006 ◽  
Vol 24 (15) ◽  
pp. 2975-2986 ◽  
Author(s):  
Danher Wang ◽  
Alan L. Schmaljohn ◽  
Nicholas U. Raja ◽  
Charles M. Trubey ◽  
Laure Y. Juompan ◽  
...  
Keyword(s):  
Immune Responses ◽  
De Novo ◽  
Marburg Virus ◽  
Cellular Immune Responses ◽  
Adenovirus Vectors ◽  
Virus Antigens ◽  
Cellular Immune

scholarly journals Induction of neutralising antibodies and cellular immune responses against SARS coronavirus by recombinant measles viruses

Vaccine ◽  
2008 ◽  
Vol 26 (17) ◽  
pp. 2164-2174 ◽  
Author(s):  
Matthias Liniger ◽  
Armando Zuniga ◽  
Azaibi Tamin ◽  
Teldja N. Azzouz-Morin ◽  
Marlyse Knuchel ◽  
...  
Keyword(s):  
Immune Responses ◽  
Sars Coronavirus ◽  
Neutralising Antibodies ◽  
Cellular Immune Responses ◽  
Cellular Immune

scholarly journals Humoral and cellular immune responses in sheep immunized with a 22 kilodalton exported protein of Mycobacterium avium subspecies paratuberculosis

2006 ◽  
Vol 55 (12) ◽  
pp. 1735-1740 ◽  
Author(s):  
Rachael C. Rigden ◽  
Dakshina M. Jandhyala ◽  
Chris Dupont ◽  
Dianna Crosbie-Caird ◽  
Nicolas Lopez-Villalobos ◽  
...  
Keyword(s):  
Immune Responses ◽  
Mycobacterium Avium ◽  
Mycobacterium Avium Subspecies Paratuberculosis ◽  
Specific Antibodies ◽  
Antibody Recognition ◽  
Cellular Immune Responses ◽  
Exported Protein ◽  
Cellular Immune

An immunogenic 22 kilodalton exported Mycobacterium avium subspecies paratuberculosis (MAP) lipoprotein (P22) was previously identified, and found to belong to the LppX/LprAFG family of mycobacterial lipoproteins. N-terminal polyhistidine-tagged P22 was produced and purified from Escherichia coli. Antibody recognition of P22, and interferon-gamma (IFN-γ) responses in vitro using blood from a sheep vaccinated with Neoparasec, confirmed its immunogenicity. To evaluate the immunogenicity of P22 in vivo, five sheep were immunized with a single dose containing 0.8 mg recombinant P22 protein in adjuvant. Blood was collected at 4, 13 and 29 weeks post-immunization (p.i.) and tested for anti-P22 antibodies and P22-specific IFN-γ production. P22-specific antibodies were detected by Western blot analysis in all five Neoparasec-immunized sheep at the three time points. Three out of five P22-immunized sheep produced P22-specific antibodies for up to 13 weeks p.i., and two gave a response at 29 weeks p.i. Recombinant P22 was able to stimulate significant IFN-γ production in blood of P22-immunized sheep at 13 and 29 weeks p.i. Recombinant P22 also elicited an IFN-γ response in blood of sheep immunized with Neoparasec.

scholarly journals ChAdOx1 and MVA based vaccine candidates against MERS-CoV elicit neutralising antibodies and cellular immune responses in mice

Vaccine ◽  
2017 ◽  
Vol 35 (30) ◽  
pp. 3780-3788 ◽  
Author(s):  
Naif Khalaf Alharbi ◽  
Eriko Padron-Regalado ◽  
Craig P. Thompson ◽  
Alexandra Kupke ◽  
Daniel Wells ◽  
...  
Keyword(s):  
Immune Responses ◽  
Neutralising Antibodies ◽  
Vaccine Candidates ◽  
Cellular Immune Responses ◽  
Cellular Immune

scholarly journals Safety and Immunogenicity of Adenovirus and Poxvirus Vectored Vaccines against a Mycobacterium Avium Complex Subspecies

Vaccines ◽  
2021 ◽  
Vol 9 (3) ◽  
pp. 262
Author(s):  
Pedro M. Folegatti ◽  
Amy Flaxman ◽  
Daniel Jenkin ◽  
Rebecca Makinson ◽  
Lucy Kingham-Page ◽  
...  
Keyword(s):  
Single Dose ◽  
T Cell ◽  
Immune Responses ◽  
Mycobacterium Avium ◽  
Mycobacterium Avium Complex ◽  
Mycobacterium Avium Subspecies Paratuberculosis ◽  
Booster Vaccine ◽  
T Cell Immune Responses ◽  
Simian Adenovirus ◽  
Vectored Vaccine

Heterologous prime-boost strategies are known to substantially increase immune responses in viral vectored vaccines. Here we report on safety and immunogenicity of the poxvirus Modified Vaccinia Ankara (MVA) vectored vaccine expressing four Mycobacterium avium subspecies paratuberculosis antigens as a single dose or as a booster vaccine following a simian adenovirus (ChAdOx2) prime. We demonstrate that a heterologous prime-boost schedule is well tolerated and induced T-cell immune responses.

Sign in / Sign up

Export Citation Format

Share Document